Video
Dr. Abramson on TRANSCEND on JCAR017 Therapy in NHL
Author(s):
Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the TRANSCEND study, which is exploring the CD19-directed chimeric antigen receptor (CAR) T-cell therapy JCAR017 in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the TRANSCEND study, which is exploring the CD19-directed chimeric antigen receptor (CAR) T-cell therapy JCAR017 in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
TRANSCEND is a phase I multicenter trial looking at the dose and safety of this cellular therapy in patients with diffuse large B-cell lymphoma and mantle cell lymphoma, Abramson says. JCAR017 has a 41BB co-stimulatory domain and a truncated EGFR receptor used to track the product in circulation and in tissue.
In the study, patients all receive a defined composition product of 1:1 of CD4 and CD8 anti-CD19 CAR T cells with JCAR017. Researchers are enrolling high-risk patients with these lymphomas who mostly are refractory to chemotherapy.
